罗欣药业属于化学制药行业，公司主营业务涵盖医药产品的研发、生产和销售。公司产品线包括抗感染 类、消化系统类、呼吸系统类等药品。 罗欣药业8月4日股价报收6.13元，较前一交易日下跌0.22元，跌幅3.46%。当日开盘价为6.23元，最高触 及6.53元，最低下探6.03元，成交量为108.18万手，成交金额6.72亿元。 风险提示：股市有风险，投资需谨慎。 8月4日盘中，罗欣药业出现快速波动。早盘9点36分出现快速反弹，5分钟内涨幅超过2%，报6.5元；随 后在9点43分又快速回调，5分钟内跌幅超过2%，报6.26元。 资金流向方面，8月4日主力资金净流入1317.26万元，占流通市值比例为0.2%。近五个交易日累计主力 资金净流入2533.91万元，占流通市值比例为0.38%。 ...

Group 1: New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - ST Kelly (300326) has a tender offer period from July 17, 2025, to August 15, 2025[1] - ST Zitian (300280) has a tender offer period ending on July 21, 2025[1] Group 2: Market Alerts - Xizang Tourism (600749) reported severe abnormal fluctuations on July 31, 2025[1] - Tianlu Convertible Bonds (110060) announced significant market activity on July 30, 2025[1] - ST Suwu (600200) experienced unusual trading patterns on July 30, 2025[1] Group 3: Additional Announcements - Happiness Blue Ocean (300528) issued a notice on July 30, 2025, regarding market conditions[1] - Common Pharmaceutical (300966) provided updates on August 1, 2025, related to stock performance[1] - Dongjie Intelligent (300486) released a statement on August 1, 2025, concerning market volatility[1]

每经AI快讯，罗欣药业（SZ 002793，最新价：6.09元）8月1日晚间发布公告称，公司第五届第二十七 次董事会会议于2025年8月1日在山东省临沂高新技术产业开发区罗七路管理中心三楼会议室和上海市浦 东新区前滩世贸中心会议室以现场表决和通讯表决相结合的方式召开。会议审议了《关于为控股子公司 提供担保的议案》等文件。 每经头条（nbdtoutiao）——"我们也深陷残酷价格战"！德资巨头中国区高管警告：智驾绝不能免费， 否则会给全行业带来灾难 （记者 王晓波） 2024年1至12月份，罗欣药业的营业收入构成为：医药工业占比89.02%，医药商业占比9.74%，其他业 务占比1.24%。 ...

Group 1 - The core point of the announcement is that Luoxin Pharmaceutical Group Co., Ltd. disclosed changes in the equity of its major shareholders, specifically a reduction in shareholding by over 1% [2][4][21] - The major shareholder Fang Xiubao and its concerted actors, including Fang Donghui and Wenzhou Daren Enterprise Management Co., Ltd., have reduced their holdings by 1,595,800 shares, representing 0.15% of the total share capital [2][4] - Following this reduction, the combined shareholding of Fang Xiubao and its concerted actors decreased from 12.10% to 11.96% [2][4] Group 2 - The company held its 27th meeting of the fifth board of directors on August 1, 2025, to discuss various matters, including providing guarantees for its subsidiary [5][6] - The board approved a proposal to provide a guarantee of RMB 20 million for its subsidiary, Luoxin Anruo Weita Pharmaceutical (Chengdu) Co., Ltd., to support its operational needs [6][28] - The guarantee proposal will be submitted to the shareholders' meeting for approval, requiring a two-thirds majority vote [8][18] Group 3 - The company announced the convening of the 2025 Fourth Extraordinary General Meeting of Shareholders on August 18, 2025, to discuss the approved proposals from the board meeting [9][32] - The meeting will be held both in-person and via online voting, allowing shareholders to participate remotely [34][39] - The registration date for shareholders to attend the meeting is set for August 11, 2025 [35][36]

Group 1 - The board of directors of Luoxin Pharmaceutical Group Co., Ltd. held its 27th meeting, which was legally convened and attended by all five directors [1] - The board approved a proposal to provide a guarantee of RMB 20 million for its subsidiary, Luoxin Anruowei Pharmaceutical (Chengdu) Co., Ltd., to support its operational and business expansion needs [1] - The guarantee will be valid for 12 months from the date of approval by the shareholders' meeting [1] Group 2 - The board proposed to convene the fourth extraordinary general meeting of shareholders in 2025 on August 18, 2025, which also received unanimous approval [2] - The proposal for the guarantee and the extraordinary general meeting will require approval from at least two-thirds of the voting rights at the shareholders' meeting [2]

Group 1 - The company announced that its fifth board of directors held the 27th meeting, where it approved a proposal to provide guarantees for its controlling subsidiary [2] - The company also approved a proposal to convene the fourth interim shareholders' meeting for the year 2025 [2]

（文章来源：证券日报） 证券日报网讯 8月1日晚间，罗欣药业发布公告称，公司第五届监事会第二十三次会议审议通过了《关 于为控股子公司提供担保的议案》。 ...

Core Viewpoint - The company, Luoxin Pharmaceutical (002793), announced that it will hold its fourth extraordinary general meeting of shareholders on August 18, 2025, to review a proposal regarding providing guarantees for its controlling subsidiary [1] Group 1 - The extraordinary general meeting is scheduled for August 18, 2025 [1] - The agenda includes a proposal to provide guarantees for a controlling subsidiary [1]

证券代码：002793 证券简称：罗欣药业 公告编号：2025-070 罗欣药业集团股份有限公司 关于为控股子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 罗欣药业集团股份有限公司（以下简称"公司"）及控股子公司对外担保 总额超过最近一期经审计净资产 100%；公司及控股子公司担保金额超过上市公 司最近一期经审计净资产 50%，提请投资者充分关注担保风险。 一、担保情况概述 为满足日常生产经营及业务拓展资金需要，保证生产经营持续发展和业务顺 利开展，公司拟为其控股子公司罗欣安若维他药业（成都）有限公司（以下简称 "罗安公司"）人民币 2,000 万元银行授信额度提供担保。具体担保金额、担保 期限等事项以各方后续签署的担保协议或担保文件约定为准。上述担保额度有效 期限自股东大会审议通过之日起 12 个月。 公司于 2025 年 8 月 1 日召开第五届董事会第二十七次会议及第五届监事会 第二十三次会议，审议通过了《关于为控股子公司提供担保的议案》。根据《深 圳证券交易所股票上市规则》《罗欣药业集团股份有限公司章程》等的相关规定， ...

证券代码：002793 证券简称：罗欣药业 公告编号：2025-071 罗欣药业集团股份有限公司 关于召开2025年第四次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 罗欣药业集团股份有限公司（以下简称"公司"）于2025年8月1日召开的第 五届董事会第二十七次会议，审议通过了《关于召开2025年第四次临时股东大会 的议案》，现将会议有关事项通知如下： 一、召开会议基本情况 1、股东大会届次：2025年第四次临时股东大会 2、股东大会的召集人：本次股东大会由公司董事会召集，经公司第五届董 事会第二十七次会议审议通过。 3、会议召开的合法、合规性：本次股东大会会议的召集、召开符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议时间：2025年8月18日（星期一）下午2:00 （2）网络投票时间：2025年8月18日 通过深圳证券交易所交易系统进行网络投票的具体时间为2025年8月18日的 交易时间，即9:15-9:25，9:30-11:30和13:00-15:00； 通过深圳证券交 ...